By reading CT scans, machine learning could aid investigators in improving treatment decision making.
The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.
Patients with advanced melanoma receiving nivolumab plus ipilimumab in the second-line setting had significant improvement in progression-free survival.
Novel BO-112 when combined with pembrolizumab may offer a new treatment option for patients with advanced melanoma and PD-1 inhibitor therapy resistance.
Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.
John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.
The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.
7HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.
Patients with unresectable or metastatic melanoma can now receive treatment with nivolumab and relatlimab-rmbw following its approval by the FDA.